Paul Anthony Williams - Jun 9, 2023 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role: SVP, Products Business
Signature: /s/ Jennifer Lynne Fox, Attorney-in-fact
Stock symbol: EBS
Transactions as of: Jun 9, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/13/2023, 09:23 PM
Previous filing: Mar 6, 2023
Next filing: Jul 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EBS	Common Stock	Award	$0	+4.62K	+37.29%	$0.00	17K	Jun 9, 2023	Direct	F1
transaction	EBS	Common Stock	Award	$0	+9.23K	+54.32%	$0.00	26.2K	Jun 9, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EBS	Employee Stock Option (Right to buy)	Award	$0	+9.23K	+68.98%	$0.00	22.6K	Jun 9, 2023	Common Stock	9.23K	$8.39	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2	Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F3	Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
F4	Represents the corrected number of securities owned due to a computational error in prior Form-4s